Related Experiment Video

Updated: Aug 6, 2026

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

[Pulmonary arterial thromboembolism and thrombophilias: optimization of diagnostics and treatment]

A V Nikitin, P V Ipatov, A N Fursov

    Klinicheskaia Meditsina
    |August 1, 2006
    PubMed

    Insights

    Nearly all pulmonary arterial thromboembolism (PATE) patients have pre-thrombotic conditions. Treating these thrombophilic conditions significantly reduces PATE recurrence and related complications.

    Area of Science:

    • Cardiology
    • Hematology
    • Genetics

    Context:

    • Pulmonary arterial thromboembolism (PATE) presents a significant clinical challenge.
    • Thrombophilic conditions (TC) are increasingly recognized as contributing factors in thromboembolic events.
    • Understanding the interplay between TC and PATE prognosis is crucial for patient management.

    Purpose:

    • To investigate the prevalence of thrombophilic conditions in PATE patients.
    • To evaluate the association between thrombophilic conditions and the clinical course of PATE.
    • To assess the impact of pharmaceutical correction of TC on PATE recurrence and outcomes.

    Summary:

    • A 3-year prospective study of 94 PATE patients found 90% had pre-thrombotic conditions.
    • Unfavorable PATE course correlated with genetic mutations, elevated Factor VIII, and cardiolipin antibodies with Factor V gene mutation.
    • Early PATE in young patients with idiopathic venous thrombosis and family history of TC predicts poor prognosis.

    Impact:

    • Targeted treatment of thrombophilic conditions significantly reduces venous thrombosis recurrence (39% to 17%).
    • Pharmaceutical correction decreases cava-filter thrombosis recurrence (24% to 3.7%) and PATE recurrence (15% to 5.6%).
    • This highlights the importance of identifying and managing TC in PATE patients for improved clinical outcomes.

    More Related Videos

    An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug07:50

    An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

    Published on: June 4, 2021

    Related Concept Videos

    Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

    Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

    Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
    Pulmonary Embolism III: Nursing Management01:27

    Pulmonary Embolism III: Nursing Management

    A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
    Pulmonary Embolism I: Introduction01:19

    Pulmonary Embolism I: Introduction

    A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
    Pulmonary Embolism I: Introduction01:29

    Pulmonary Embolism I: Introduction

    Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
    Venous Thrombosis III: Interprofessional Care01:29

    Venous Thrombosis III: Interprofessional Care

    Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
    Pulmonary Hypertension: Classification and Pathogenesis01:30

    Pulmonary Hypertension: Classification and Pathogenesis

    Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
    There are various classifications for PH, each relating to different underlying causes and also...